FDA approves 6-month HIV prevention shot

Pharmaceutical institution Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was recovered successful trials to beryllium much than 99.9 percent effectual among participants. Gilead’s merchandise Yeztugo, a signifier of lenacapavir, was approved for reducing the hazard of sexually acquired HIV successful adults and adolescents…